Short answer
ADMA BIOLOGICS, INC. (ADMA) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $124M (up 2.0% year over year) with net income of $38M.
Q2 2026 key financials · XBRL
- Revenue
- $124M
- +2.0% YoY · +8.6% QoQ
- Net income
- $38M
- +10.5% YoY · −16.6% QoQ
- Operating margin
- 42.2%
- Gross margin
- 69.4%
- EPS (diluted)
- $0.16
- +14.3% YoY · −15.8% QoQ
Source: XBRL data from the ADMA BIOLOGICS, INC. (ADMA) Q2 2026 10-Q on SEC EDGAR. USD.
ADMA BIOLOGICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $124.4M, up 2.0% YoY from $122.0M
- Gross margin 69.4% vs 55.1% YoY
- ASCENIV revenue $102.9M, up 23.5%; BIVIGAM $19.4M, down 48.5%
- Net income $37.8M vs $34.2M YoY
- Competitive pricing pressure across IVIG markets, particularly BIVIGAM, affecting first-half 2026 results
Risk Factors
- Newly added AI risk, triggered by development and use of artificial intelligence, creating potential reputational harm and increased liability exposure
- Securities litigation risk, with ADMA and directors and officers named as defendants in a class action lawsuit
- FDA compliance risk, where inspections may produce Form 483 observations, warning letters, recalls, or supply disruptions
- Supply-chain risk, with third-party fill-finishers and plasma suppliers potentially delaying finished-product availability
- Customer concentration risk, as a few customers historically represented significant revenue and accounts receivable exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADMA BIOLOGICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.